Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J07BB02

Flucelvax(A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022 CVR-167) / A/District of Columbia/27/2023 (H3N2)-like strain (A/Victoria/800/2024 CVR-289) / B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021))

Influenza, Human

Marketing Authorisation Holder: Seqirus Netherlands B.V.

EMA Authorisation: 15/11/2024

INN: influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

Indication

Prophylaxis of influenza in adults and children from 6 months of age. Flucelvax should be used in accordance with official recommendations.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Flucelvax — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about FlucelvaxCreate Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.